Form 4: Precigen Director Sells $8.3M in Shares

Precigen's Director and 10% owner, Randal J. Kirk, reported the sale of nearly 2 million shares of common stock for approximately $8.3 million.

Summary

• Randal J. Kirk, a Director and 10% owner of Precigen, Inc. (PGEN), sold a total of 1,990,036 shares of common stock.
• The sales occurred on December 22, 2025, at a weighted average price of $4.18 per share, totaling approximately $8,318,351.08.
• The shares were sold in multiple transactions ranging from $4.1800 to $4.1900 per share.
• The transactions were executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale.
• Following these transactions, Randal J. Kirk, through various controlled entities and his spouse, still beneficially owns a significant number of shares, totaling approximately 122,049,584 shares.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative due to a significant insider sale by a key director and 10% owner. While the sale was pre-planned under a 10b5-1 plan, the substantial value of the shares sold (over $8.3 million) could still be interpreted by the market as a lack of strong conviction or a need for liquidity, potentially impacting investor confidence.

Positives

• The sale was conducted under a Rule 10b5-1(c) plan, which suggests the transaction was pre-scheduled and not necessarily based on new, adverse material non-public information.
• Randal J. Kirk retains a substantial beneficial ownership of approximately 122 million shares, indicating continued alignment with shareholder interests.

Negatives

• A significant insider sale by a Director and 10% owner, totaling nearly 2 million shares for over $8.3 million, can be perceived negatively by the market.
• Such a large sale, even if pre-planned, might signal a lack of confidence in the company's near-term growth prospects or a personal need for liquidity.

Risks

• The market may interpret the significant insider sale as a negative signal, potentially leading to downward pressure on Precigen's stock price.
• Investor confidence could be impacted if the sale is perceived as a lack of belief in the company's future by a key insider.

Future Outlook

NA

Industry Context

Insider sales, particularly by significant shareholders and directors, are closely watched in the biotechnology and pharmaceutical sectors as they can sometimes precede significant company news or shifts in strategic direction. While this sale is under a 10b5-1 plan, its size could still draw attention in a sector often sensitive to investor sentiment and capital flows.

Comparison to Industry Standards

• This filing is a transaction report, not a performance report, so direct comparison to industry standards for operational results is not applicable.
• Insider selling is a common event across industries, and the market generally views large sales by key insiders with caution, even if pre-planned.

Related Party Transactions

• The sale of shares by Randal J. Kirk, a Director and 10% owner, and entities he controls (R.J. Kirk Declaration of Trust, JPK 2008 LLC, JPK 2009 LLC, JPK 2012 LLC, MGK 2008 LLC, MGK 2009 LLC, MGK 2011 LLC, ZSK 2008 LLC, ZSK 2009 LLC, Kellie L. Banks (2009) Long Term Trust, Kapital Joe, LLC, Lotus Capital (2000) Company, Inc., Third Security, LLC, Parkview 2020 Limited Partnership, Sunset 2020 LLC, and his Spouse) constitutes related party transactions.

Stakeholder Impact

• Shareholders: May react negatively to the significant insider sale, potentially leading to a decrease in share price due to perceived lack of confidence from a major owner.
• Employees: No direct impact mentioned, but a decline in stock price could affect equity-based compensation.

Key Dates

Recommendation

While the significant insider sale by a Director and 10% owner is a negative signal, the transaction was executed under a Rule 10b5-1 plan, suggesting it was pre-scheduled rather than reactive to new negative information. Furthermore, Randal J. Kirk retains a very substantial beneficial ownership in Precigen, indicating continued long-term interest. Given these mixed signals, a 'hold' recommendation is appropriate, advising investors to monitor future company developments and insider activity before making further investment decisions.

Keywords

Precigen, PGEN, Insider Sale, Form 4, Randal J. Kirk, Director, 10% Owner, Stock Sale, Equity Transaction, Rule 10b5-1